Indefinite Delivery Contract W81K0225DA013
- Not listed
- Roche Diagnostics Corporation was awarded a single-award Indefinite Delivery Contract by the Defense Health Agency on October 1, 2021, for the supply of histology test reagents and Roche Diagnostics Ventana Medical System platform reagents. The indefinite delivery vehicle maintains a ceiling value of $1,774,824.38 and extends through September 30, 2026, with no set-aside designation. The contract was awarded on an open competitive basis and represents a firm-fixed-price arrangement under which...
- The Defense Health Agency awarded a single-award Indefinite Delivery Contract to Roche Diagnostics Corporation for a fully automated sample preparation and consultation system supporting the Department of Pathology and Area Laboratory Services histology laboratory at Brooke Army Medical Center (BAMC) in Fort Sam Houston, Texas. The contract, valued at $6.75 million with a period of performance from October 1, 2025, through September 30, 2029, was awarded without set-aside designation to this...
- The Defense Health Agency awarded a single-award Blanket Purchase Agreement to Roche Diagnostics Corporation for the leasing of tissue staining equipment, services, and reagents with a ceiling value of $20,000,000 and a period of performance through May 4, 2030. This contract was awarded on May 1, 2025, without any set-aside designation, allowing Roche to compete openly in the federal marketplace. The contract vehicle enables the Defense Health Agency to efficiently procure diagnostic laboratory...
- The Defense Health Agency awarded a single-award Indefinite Delivery Contract to Roche Diagnostics Corporation on October 1, 2023, with a ceiling value of $10,938,777.37 and an ultimate completion date of September 30, 2028. This contract procures chemistry and immunoassay testing supplies and services under a cost-per-reportable-result pricing model. Roche Diagnostics Corporation, a foreign-owned manufacturer of in vitro diagnostics, reagents, laboratory instruments, and associated medical...
- Roche Diagnostics Corporation, a foreign-owned manufacturer of in vitro diagnostics and laboratory reagents, was awarded a single-award Indefinite Delivery Indefinite Quantity (IDIQ) contract by the Defense Health Agency on September 23, 2022, with a ceiling value of $6.5 million and an ultimate completion date of September 22, 2027. The contract covers Roche Diagnostics Laboratory Library Preparation Kits and related consumable laboratory test and quantification materials. The primary places of...
- Roche Diagnostics Corporation, a foreign-owned manufacturer of in vitro diagnostics and laboratory instruments, received a single-award Indefinite Delivery Contract from the Defense Health Agency (DHA) on October 1, 2023, with a ceiling value of $7.42 million and an ultimate completion date of June 30, 2028. The contract procures chemistry reagents to support laboratory diagnostic operations across military and defense healthcare systems. The IDV does not utilize small business set-asides,...
- This Indefinite Delivery Contract (IDC) was awarded by the Defense Health Agency (DHA), a defense agency, to Roche Diagnostics Corporation, a foreign-owned, for-profit manufacturer of in vitro diagnostics, reagents, and laboratory instruments. The $3.66 million, single-award IDC provides an indefinite quantity of immunohistochemical (IHC) testing services, slide stainers, cytology/histology reagents, and associated consumables in support of the Naval Medical Center in Portsmouth, Virginia. The...
- The provided information details an Indefinite Delivery Contract (IDC) awarded by the Defense Health Agency (DHA) to Roche Diagnostics Corporation, a manufacturer and distributor of in vitro diagnostics, laboratory instruments, and associated products and services. The 5-year, $9,160,241.71 IDC allows DHA to issue delivery orders for Roche's Total Laboratory Automation Systems and Cobas 8000 analyzers to support operations at Madigan Army Medical Center in Tacoma, Washington. Under the IDC,...
- The Department of Veterans Affairs, Veterans Health Administration (VA-VHA) has awarded an Indefinite Delivery Contract (IDC) worth up to $3,118,396.46 to Roche Diagnostics Corporation to provide immunohistochemistry cost per test services. This single-award IDC has a period of performance through September 30, 2027. Under this contract, Roche Diagnostics has been issued a series of firm-fixed price delivery orders to perform immunohistochemistry testing services in support of VA healthcare...
- Roche Diagnostics Corporation has been awarded an indefinite delivery contract by the Department of the Army Medical Command to provide immunochemistry testing services. The single award contract has a potential value of $16.6M and period of performance through September 2023. Under the contract vehicle, Roche has received multiple delivery orders to conduct clinical chemistry and immunoassay testing at its facility in Castleton, Indiana for various Army medical treatment facilities. Orders have...
- W81K0225DA013Indefinite Delivery Contract
- 1Federal Contract Awards
Roche Diagnostics Corporation has been awarded a single-award Indefinite Delivery Contract with the Defense Health Agency to provide automated immunohistochemistry (IHC) and in-situ hybridization (ISH) slide staining platforms, antibody stains, reagents, and supplies supporting the anatomic pathology mission at Madigan Army Medical Center. The contract, effective October 1, 2025, carries a ceiling value of $1.5 million with an ultimate completion date of September 30, 2030. No set-aside designation was used in this procurement. The contract vehicles enable the Defense Health Agency to efficiently acquire diagnostic technologies through pre-negotiated pricing and terms for histopathology laboratory operations. Under this Indefinite Delivery Contract, an initial Delivery Order valued at approximately $297,929 was awarded on October 1, 2025, with a firm fixed price arrangement and a September 30, 2030 completion date. This task order specifically procures the IHC and ISH automated platform, supporting the histology laboratory's clinical diagnostic function by enabling pathologists and clinicians to assess disease status in biopsy tissue samples for accurate diagnosis. The place of performance is Joint Base Lewis-McChord, Washington, USA. As a global leader in diagnostic solutions, Roche Diagnostics brings significant technical expertise in specialized laboratory instrumentation and reagent provision, addressing the military healthcare system's need for advanced pathology diagnostic capabilities.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $0 | 9/16/25 |
Name | Description | Awardee | Potential Value | AwardDate | CompletionDate | Updated At |
|---|---|---|---|---|---|---|
Delivery Order W81K0225DA013-W81K0225FA137 | Roche Diagnostics Corporation | $297.9k | 10/1/25 | 9/30/30 | 9/16/25 |